Upper GI cancers, including esophageal, stomach, and pancreatic cancers, remain the second leading cause of cancer-related deaths in the U.S. Gastroenterologists, with their expertise in endoscopic ultrasound (EUS), are uniquely positioned to lead the integration of emerging cancer therapies such as targeted radiotherapy. These minimally invasive, EUS-guided treatments allow for precise intratumoral delivery, especially in pancreatic cancer where surgery is often not viable. As treatment models become more collaborative and personalized, GIs are at the forefront of a care revolution—poised to drive innovation, expand access to localized therapies, and improve patient outcomes.
Trending
- 7 HLTH Announcements You Don’t Want to Miss (MedCity News)
- Practical Tips for Contracting, Part 2 (GI & Endoscopy News)
- GRAIL PATHFINDER 2 Results Show Galleri® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings (GRAIL)
- Eliminating Cost Sharing Boosted Follow-Up Colonoscopy Rates (AJMC)
- St. Charles Health System Taps WovenX to Transform GI Access and Optimize Capacity (PR Newswire)
- United Digestive adds 5 gastroenterologists in 3 months (Becker’s GI & Endoscopy)
- Negotiated Prices for Large Insurers and Regional Differences in Employed Cardiology and GI Groups Revealed (Medscape)
- Health care in the USA: money has become the mission (The Lancet)
